Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Gefitinib (Iressa, ZD-1839), a small molecule tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR) pathway, is currently under investigation in clinical trials for the treatment of colorectal cancer (CRC). However, as known, some patients develop resistance to TKIs and the mechanisms mediating intrinsic resistance to EGFR-TKIs in CRC have not been fully characterized. Resistance to EGFR inhibitors reportedly involves activation of signal transducer and activator of transcription 3 (STAT3) in glioma and lung cancer. Here, we demonstrated that the nuclear pyruvate kinase isoform M2 (PKM2) levels were positively correlated with gefitinib resistance in CRC cells. The overexpression of nuclear PKM2 in HT29 cells decreased the effect of gefitinib therapy, whereas PKM2 knockdown increased gefitinib efficacy. Furthermore, the activation of STAT3 by nuclear PKM2 was associated with gefitinib resistance. Inhibition of STAT3 by Stattic, a STAT3-specific inhibitor, or STAT3-specific siRNA sensitized resistant cells to gefitinib. These results suggest that nuclear PKM2 modulates the sensitivity of CRC cells to gefitinib and indicate that small molecule pharmacological disruption of nuclear PKM2 association with STAT3 is a potential avenue for overcoming EGFR-TKI resistance in CRC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, nuclear pyruvate kinase isoform M2 (PKM2) promotes gefitinib resistance by upregulation of STAT3 activation in CRC, and inhibition of STAT3 or PKM2 can reverse CRC against EGFR resistance [204].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [204]
In the citing paper
“In addition, nuclear pyruvate kinase isoform M2 (PKM2) promotes gefitinib resistance by upregulation of STAT3 activation in CRC, and inhibition of STAT3 or PKM2 can reverse CRC against EGFR resistance [204].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [204]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820 · cited 1×
“Most adult tissues of mammals express the M1 isoform, while the M2 isoform, which is a variant resulting from M1 splicing, is expressed in embryonic and tumor tissues 13 .”
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
TRANSCRIPTIONAL RESPONSES TO POLYPEPTIDE LIGANDS: The JAK-STAT Pathway
Schindler, C., & Darnell, J. E. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.003201 · Cited by 1,808
Pyruvate Kinase M2 Is a PHD3-Stimulated Coactivator for Hypoxia-Inducible Factor 1
Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O'Meally, R., Cole, R. N., Pandey, A., & Semenza, G. L. (2011) · Cell · doi:10.1016/j.cell.2011.03.054 · Cited by 1,463
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K., & Lu, Z. (2011) · Nature · doi:10.1038/nature10598 · Cited by 1,028
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., Lyssiotis, C. A., Aldape, K., Cantley, L. C., & Lu, Z. (2012) · Nature Cell Biology · doi:10.1038/ncb2629 · Cited by 918
Self-citationPyruvate kinase type M2 and its role in tumor growth and spreading
Mazurek, S., Boschek, C. B., Hugo, F., & Eigenbrodt, E. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.04.009 · Cited by 812
Pyruvate Kinase M2 Regulates Gene Transcription by Acting as a Protein Kinase
Gao, X., Wang, H., Yang, J. J., Liu, X., & Liu, Z.-R. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.001 · Cited by 772 · cited 8×
“3D), which suggested that Y705 was the single activation site for PKM2 in the nuclear extracts.”
Influential
Cited by
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Advances in targeted therapy for esophageal cancer
Yang, Y.-M., Hong, P., Xu, W. W., He, Q.-Y., & Li, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00323-3 · Cited by 508
PKM2, function and expression and regulation
Zhang, Z., Deng, X., Liu, Y., Liu, Y., Sun, L., & Chen, F. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0317-8 · Cited by 498
Celada, L. J., Kropski, J. A., Herazo-Maya, J. D., Luo, W., Creecy, A., Abad, A. T., Chioma, O. S., Lee, G., Hassell, N. E., Shaginurova, G. I., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar8356 · Cited by 363
Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
Zhao, B., Wang, L., Qiu, H., Zhang, M., Sun, L., Peng, P., Yu, Q., & Yuan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14012 · Cited by 319
“investigated the mechanism underlying the disappointing effect of the EGFR inhibitor gefitinib in CRC cells, and found that STAT3 phosphorylation (pSTAT3) highly correlated with gefitinib resistance in CRC cells [72].”
BackgroundYang, Y., Li, S., Wang, Y., Zhao, Y., & Li, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01168-8 · Cited by 294
Self-citationBian, Z., Zhang, J., Li, M., Feng, Y., Wang, X., Zhang, J., Yao, S., Jin, G., Du, J., Han, W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2967 · Cited by 305
Self-citationSTAT proteins in cancer: orchestration of metabolism
Li, Y.-J., Zhang, C., Martincuks, A., Herrmann, A., & Yu, H. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00537-3 · Cited by 282
Hsu, M.-C., & Hung, W.-C. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0791-3 · Cited by 179
STAT3 pathway in cancers: Past, present, and future
Wang, H., Man, Q., Huo, F., Gao, X., Lin, H., Li, S., Wang, J., Su, F., Cai, Shi, Y., et al. (2022) · MedComm · doi:10.1002/mco2.124 · Cited by 169
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Huang, Y., Sun, G., Sun, X., Li, F., Zhao, L., Zhong, R., & Peng, Y. (2020) · Cancers · doi:10.3390/cancers12113332 · Cited by 124
Amin, S., Yang, P., & Li, Z. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.02.003 · Cited by 134
The roles of signal transducer and activator of transcription factor 3 in tumor angiogenesis
Gao, P., Niu, N., Wei, T., Tozawa, H., Chen, X., Zhang, W., Zhang, J., Wada, Y., Kapron, C. M., & Liu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.19932 · Cited by 122
Self-citationPKM2, a potential target for regulating cancer
Li, Y., Li, X., Liu, J., Wang, H., Fan, L., Li, J., & Sun, G. (2018) · Gene · doi:10.1016/j.gene.2018.05.038 · Cited by 107
Zheng, Q., Dong, H., Mo, J., Zhang, Y., Huang, J., Ouyang, S., Shi, S., Zhu, K., Qu, X., Hu, W., et al. (2020) · Theranostics · doi:10.7150/thno.49600 · Cited by 110
Protein kinase function of pyruvate kinase M2 and cancer
Chen, X., Chen, S., & Yu, D. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01612-1 · Cited by 110
Self-citationCell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy
Sobanski, T., Rose, M., Suraweera, A., O'Byrne, K. J., Richard, D. J., & Bolderson, E. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.633305 · Cited by 98
Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer
Aguilera, O., Muñoz-Sagastibelza, M., Torrejón, B., Borrero-Palacios, A., del Puerto-Nevado, L., Martínez-Useros, J., Rodriguez-Remirez, M., Zazo, S., García, E., Fraga, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10087 · Cited by 84
Yang, Q., Chen, W., Yu-feng, X., Lv, X., Zhang, M., & Jiang, H. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.07.031 · Cited by 80
Novel Insights on Lipid Metabolism Alterations in Drug Resistance in Cancer
Yang, R., Yi, M., & Xiang, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.875318 · Cited by 86
Li, Q., Li, Y., Xu, J., Wang, S., Xu, Y., Li, X., & Cai, S. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477484 · Cited by 72
Self-citationGuo, M., Zhao, X., Yuan, X., Jiang, J., & Li, P. (2017) · Oncotarget · doi:10.18632/oncotarget.15999 · Cited by 63
STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
Zulkifli, A., Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.010 · Cited by 61
Metabolic alterations mediated by STAT3 promotes drug persistence in CML
Patel, S. B., Nemkov, T., Stefanoni, D., Benavides, G. A., Bassal, M. A., Crown, B. L., Matkins, V. R., Camacho, V., Kuznetsova, V., Hoang, A. T., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01315-0 · Cited by 56
Suzuki, A., Puri, S., Leland, P., Puri, A., Moudgil, T. L., Fox, B. A., Puri, R. K., & Joshi, B. H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217131 · Cited by 60
Nagasawa, I., Muroi, M., Kawatani, M., Ohishi, T., Ohba, S., Kawada, M., & Osada, H. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.11.010 · Cited by 56
Yu, P., Li, A.-X., Chen, X., Tian, M., Wang, H.-Y., Wang, X., Zhang, Y., Wang, K.-S., & Cheng, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.550469 · Cited by 54
Self-citationThe Multifarious Functions of Pyruvate Kinase M2 in Oral Cancer Cells
Kurihara‐Shimomura, M., Sasahira, T., Nakashima, C., Kuniyasu, H., Shimomura, H., & Kirita, T. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102907 · Cited by 55
Hashemi, M., Abbaszadeh, S., Rashidi, M., Amini, N., Anaraki, K. T., Motahhary, M., Khalilipouya, E., Nashtifani, A. H., Shafiei, S., Farani, M. R., et al. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116458 · Cited by 56
Rathod, B., Chak, S., Patel, S., & Shard, A. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00045d · Cited by 49
Comprehensive review of the resistance mechanisms of colorectal cancer classified by therapy type
Oh, J. M., Kim, S. W., Tsung, C., Kent, E. W., Jain, A., Ruff, S. M., & Zhang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571731 · Cited by 56
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2
Arora, S., Joshi, G., Chaturvedi, A., Heuser, M., Patil, S. N., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00981 · Cited by 49
Targeting pyruvate kinase muscle isoform 2 (PKM2) in cancer: What do we know so far?
Chhipa, A. S., & Patel, S. S. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119694 · Cited by 46
Cisplatin Resistance and Redox-Metabolic Vulnerability: A Second Alteration
Wangpaichitr, M., Theodoropoulos, G., Nguyen, D. J. M., Wu, C., Spector, S. A., Feun, L. G., & Savaraj, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147379 · Cited by 47
The role of glycolysis in tumorigenesis: From biological aspects to therapeutic opportunities
Cordani, M., Michetti, F., Zarrabi, A., Zarepour, A., Rumio, C., Strippoli, R., & Marcucci, F. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101076 · Cited by 40
The role of pyruvate kinase M2 in anticancer therapeutic treatments (Review)
Su, Q., Luo, S., Tan, Q., Deng, J., Zhou, S., Peng, M., Tao, T., & Yang, X. (2019) · Oncology Letters · doi:10.3892/ol.2019.10948 · Cited by 49
Guesmi, F., Tyagi, A. K., Prasad, S., & Landoulsi, A. (2018) · Oncotarget · doi:10.18632/oncotarget.25955 · Cited by 39
“This data is supported by another report showing the ability of STAT-3 to phosphorylate in HCT116 cell lines [49].”
ResultXiao, M., Xie, J., Wu, Y., Wang, G., Qi, X., Liu, Z., Wang, Y., Wang, X., Hoque, A., Oakhill, J. S., et al. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0528-y · Cited by 41
Lin, H., Han, H., Yang, M., Wen, Z., Chen, Q., Ma, Y., Wang, X., Wang, C., Yin, T., Wang, X., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115166 · Cited by 39
Lyu, H., Petukhov, P. A., Banta, P. R., Jadhav, A., Lea, W., Cheng, Q., Arnér, E. S. J., Simeonov, A. M., Thatcher, G. R. J., Angelucci, F., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00354 · Cited by 38
Wang, J., Zhang, G., Dai, C., Gao, X., Wu, J., Shen, L., Chen, Z., & Liu, P. (2017) · Journal of International Medical Research · doi:10.1177/0300060516685513 · Cited by 35
Tian, Z., Cen, L., Feng, W., Dong, J., Huang, Y., Han, Y., Wang, Z., Deng, J., & Jiang, Y. (2025) · Oncology Letters · doi:10.3892/ol.2025.15121 · Cited by 40
FEZF1-AS1: a novel vital oncogenic lncRNA in multiple human malignancies
Shi, C., Sun, L., & Song, Y. (2019) · Bioscience Reports · doi:10.1042/bsr20191202 · Cited by 35
A critical review of the role of M2PYK in the Warburg effect
Harris, R. A., & Fenton, A. W. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.004 · Cited by 32
Hwang, S. R., Murga‐Zamalloa, C., Brown, N. A., Basappa, J., McDonnell, S. R. P., Mendoza‐Reinoso, V., Basrur, V., Wilcox, R. A., Elenitoba‐Johnson, K. S. J., & Lim, M. S. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.39 · Cited by 31
Yoon, Y. J., Kim, Y. H., Jin, Y., Chi, S., Moon, J. H., Han, D. C., & Kwon, B. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.07.015 · Cited by 33
Down‐regulation of PKM 2 enhances anticancer efficiency of THP on bladder cancer
Su, Q., Tao, T., Tang, L., Deng, J., Darko, K. O., Zhou, S., Peng, M., He, S., Zeng, Q., Chen, A. F., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13571 · Cited by 31
The interaction between apigenin and PKM2 restrains progression of colorectal cancer
Shi, J., Ji, X., Shan, S., Zhao, M., Bi, C., & Li, Z. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109430 · Cited by 32
Wang, L., Kong, L., Liu, H., Zhang, Y., Zhang, L., Liu, X., Yuan, F., Li, Y., & Zuo, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111665 · Cited by 29
Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All
Martins, M., Mansinho, A., Cruz-Duarte, R., Lobo-Martins, S., & Costa, L. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-02771-1_8 · Cited by 30
Lis, C., Rubner, S., Roatsch, M., Berg, A., Gilcrest, T., Fu, D., Nguyen, E. D., Schmidt, A.-M., Krautscheid, H., Meiler, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17600-x · Cited by 30
Al‐Maleki, A. R., Loke, M. F., Lui, S. Y., Ramli, N. S. K., Khosravi, Y., Ng, C. G., Gopinath, V., Goh, K., Ho, B., & Vadivelu, J. (2017) · Cellular Microbiology · doi:10.1111/cmi.12771 · Cited by 31
Ge, X., Zhao, Y., Dong, L., Jingjing, S., Zhang, X., & Dou, D. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28910 · Cited by 30
Xiao-ling, Y. A. N., Zhang, X., Ao, R., & Guan, L. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26148 · Cited by 27
RetractedHMGCR inhibition stabilizes the glycolytic enzyme PKM2 to support the growth of renal cell carcinoma
Huang, J., Zhao, X., Li, X., Peng, J., Yang, W., & Mi, S. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001197 · Cited by 26
Targeting PKM2 promotes chemosensitivity of breast cancer cells in vitro and in vivo
Wang, Y., Zhao, H., Zhao, P., & Wang, X. (2021) · Cancer Biomarkers · doi:10.3233/cbm-210111 · Cited by 23
Inhibiting Protein Kinase Activity of Pyruvate Kinase M2 by SIRT2 Deacetylase Attenuates Psoriasis
Hao, L., Park, J., Jang, H., Bae, E. J., & Park, B. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.06.024 · Cited by 24
On the Role of Glycolysis in Early Tumorigenesis—Permissive and Executioner Effects
Marcucci, F., & Rumio, C. (2023) · Cells · doi:10.3390/cells12081124 · Cited by 26
Upadhyay, S., Bhardwaj, M., Kumar, S. P., Khan, S., Kumar, A., & Hassan, M. I. (2025) · Biochemistry · doi:10.1021/acs.biochem.5c00009 · Cited by 21
Wang, J., Wang, Y., Zheng, C., Hou, K., Zhang, T., Qu, X., Liu, Y., Kang, J., Hu, X., & Che, X. (2018) · Cell Biology International · doi:10.1002/cbin.11000 · Cited by 24
Tang, J., Long, F., Zhao, J., Hang, J., Ren, Y., Chen, J.-Y., & Mu, B. (2019) · Journal of Cancer · doi:10.7150/jca.30361 · Cited by 20
TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells
Cui, Z., Liu, Z., Zeng, J., Zhang, S., Chen, L., Zhang, G., Xu, W., Song, L., & Guo, X. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.041 · Cited by 19
Kim, H.-J., Kim, S. H., Hwang, D., An, J., Chung, H. S., Yang, E. G., & Kim, S. Y. (2019) · Biochemistry and Cell Biology · doi:10.1139/bcb-2019-0139 · Cited by 23
Zou, K., Wang, Y., Hu, Y., Zheng, L., Xu, W., & Li, G. (2017) · Tumor Biology · doi:10.1177/1010428317695962 · Cited by 18
Interplay Between Glucose Metabolism and Chromatin Modifications in Cancer
Ma, R., Wu, Y., Li, S., & Yu, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.654337 · Cited by 23
Han, X., Li, L., Dong, B., Lu, J., Zhou, K., Yin, X., & Sun, H. (2023) · Cancer Medicine · doi:10.1002/cam4.6552 · Cited by 16
Non-metabolic enzyme function of PKM2 in hepatocellular carcinoma: A review
Zhang, S., Liao, Z., Li, S., & Luo, Y. (2023) · Medicine · doi:10.1097/md.0000000000035571 · Cited by 17
Park, W., Han, J. H., Wei, S., Yang, E.-S., Cheon, S.-Y., Bae, S., Ryu, D., Chung, H., & Ha, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020807 · Cited by 25
Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma
Zerhouni, M., Martin, A. R., Furstoss, N., Gutierrez, V., Jaune, E., Tekaya, N., Béranger, G. E., Abbe, P., Regazzetti, C., Amdouni, H., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2114 · Cited by 18
Non-metabolic functions of Pyruvate kinase M2: PKM2 in tumorigenesis and therapy resistance
İlhan, M. (2022) · Neoplasma · doi:10.4149/neo_2022_220119n77 · Cited by 17
Zhuang, Q.-S., Sun, X., Chong, Q.-Y., Banerjee, A., Zhang, M., Wu, Z., Zhu, T., Pandey, V., & Lobie, P. E. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.712348 · Cited by 16
A Comprehensive Review on Targeted Cancer Therapy: New Face of Treatment Approach
Karati, D., & Kumar, D. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128272203231121034814 · Cited by 19
Gan, L., Li, Q., Nie, W., Zhang, Y., Jiang, H., Tan, C., Zhang, L., Zhang, J., Li, Q., Hou, P., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.73530 · Cited by 16
Self-citationDevelopment of isoselenazolium chlorides as selective pyruvate kinase isoform M2 inhibitors
Dimitrijevs, P., Makrecka‐Kuka, M., Bogucka, A., Hyvönen, M., Panteļejevs, T., & Arsenyan, P. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115504 · Cited by 14
Jin, L., Lu, H.-J., Shao, J.-K., Wang, Y., Lu, S.-P., Huang, B., Hu, G., Jin, H., & Wang, C. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04907-9 · Cited by 16
Yang, H., Mo, C., Xun, Y., Liu, L. G., Li, W., Guan, J., Liu, J., Wu, J., Yang, A., Zheng, S., et al. (2019) · PubMed · Cited by 15
Liao, Q., Feng, X., Li, X., Chen, G., Chen, J., Yang, B., Li, K., & Ai, J. (2020) · Oncology Reports · doi:10.3892/or.2020.7660 · Cited by 15
Li, R., Ning, X., He, J., Lin, Z., Su, Y., Li, R., & Yin, Y. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104653 · Cited by 15
Ziranu, P., Lai, E., Schirripa, M., Puzzoni, M., Persano, M., Pretta, A., Munari, G., Liscia, N., Pusceddu, V., Loupakis, F., et al. (2021) · Targeted Oncology · doi:10.1007/s11523-021-00816-3 · Cited by 15
Yuan, X., Cao, L., Hu, Y., Bao, F., Wang, Z.-T., Cao, J., Yuan, P., Lv, W., & Hu, J. (2017) · Tumor Biology · doi:10.1177/1010428317694309 · Cited by 13
PKM2 aggravates palmitate-induced insulin resistance in HepG2 cells via STAT3 pathway
Chen, L., Tang, Z., Wang, X., Ma, H., Shan, D., & Cui, S. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.08.025 · Cited by 12
Tumor pyruvate kinase M2: A promising molecular target of gastrointestinal cancer
Chen, G., Guan, L., Hou, J., Deng, X., Ao, S., Li, Z., & Lyu, G. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.06.11 · Cited by 12
Y-320, a novel immune-modulator, sensitizes multidrug-resistant tumors to chemotherapy.
Hong, J., Jing, S., Zhang, Y., Chen, R., Owusu-Ansah, K. G., Chen, B., Xie, H., Zhou, L., Zheng, S., & Jiang, D. (2020) · PubMed Central · Cited by 11
Zheng, J., Yu, J. A., Yang, M. H., & Tang, L. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7754 · Cited by 11
Peng, J., Huang, H., Huan, Q., Liao, C., Guo, Z., Hu, D., Shen, X., & Xiao, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.847088 · Cited by 11
Galectin-3 levels are elevated following nintedanib treatment
Shochet, G. E., Pomerantz, A., Shitrit, D., Bardenstein-Wald, B., Ask, K., Surber, M. W., Rabinowicz, N., Levy, Y. M., Benchetrit, S., Edelstein, E., et al. (2020) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622320968412 · Cited by 9
Yanagimichi, M., Nishino, K., Sakamoto, A., Kurodai, R., Kojima, K., Eto, N., Isoda, H., Ksouri, R., Irie, K., Kambe, T., et al. (2020) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2020.100882 · Cited by 11
Zhao, L., Cheng, J., Zheng, Y., Wu, J., Fan, J., Sun, H., & Gao, C. (2025) · International Journal of Cancer · doi:10.1002/ijc.70091 · Cited by 11
Singla, P., & Jain, A. K. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122719 · Cited by 8
Gu, H., You, W., Zhou, X., Wang, Z., Huo, S., Nie, X., Feng, Y., You, Y., Zhan, X., & Xia, L. (2025) · ACS Omega · doi:10.1021/acsomega.5c01251 · Cited by 5
The moonlighting functions of glycolytic enzymes in tumorigenesis
Chen, X., Yang, J., & Ma, Y. (2026) · Cellular Oncology · doi:10.1007/s13402-025-01135-9 · Cited by 7
Self-citationRare diseases and pyruvate kinase M2: a promising therapeutic connection
Kapoor, S., Kalmegh, V., Kumar, H., Mandoli, A., & Shard, A. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.103949 · Cited by 6
A natural PKM2 targeting agent as a potential drug for breast cancer treatment
Shang, X., Wang, Y.-J., Hou, Z., Wang, X., Zhang, H., Yang, C., Li, J., Huang, X., Song, S., & Yao, G. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.1157 · Cited by 4
Long, Y., Xu, J., Xu, Z., Su, Z., Li, W., & Li, J. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119692 · Cited by 3
Kim, S. H., Wi, J. H., Gwak, H., Yang, E. G., & Kim, S. Y. (2022) · Biomolecules · doi:10.3390/biom12081082 · Cited by 4
Aalami, A. H., Shahriari, A., Mazaheri, M., Aalami, F., Amirabadi, A., & Sahebkar, A. (2023) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2023.110652 · Cited by 3
Pyruvate kinase M2 modulates Japanese encephalitis virus replication in neuronal cells
Bohara, V. S., Deshmukh, A., & Kumar, S. (2025) · Journal of General Virology · doi:10.1099/jgv.0.002140 · Cited by 4
Natural products combating EGFR-TKIs resistance in cancer
Li, X., Zhu, G., Peng, Q., Li, X., Zou, X., Zhang, W., Zhao, L., Li, X., Wu, P., Luo, A., et al. (2025) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2025.100251 · Cited by 5
Landscape of Current Targeted Therapies for Advanced Colorectal Cancer
Pissarra, A. J., Abreu, C., Mansinho, A., Costa, A. L., Dâmaso, S., Lobo-Martins, S., Martins, M., & Costa, L. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.93978 · Cited by 1
Metadata
- Authors
- Li, Q., Zhang, D., Chen, X., He, L., Li, T., Xu, X., & Li, M.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Washington University in St. Louis (US)
- Corresponding author
- Li, Min
- Venue
- Scientific Reports
- Published
- 2015-11-06
- Volume
- 5
- Issue
- 1
- Pages
- 16082-16082
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC4635355
- OpenAlex
- W2195075045
- Cited by
- 114
- References
- 32
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 7 · 2023: 14 · 2022: 9 · 2021: 15 · 2020: 13 · 2019: 15 · 2018: 12 · 2017: 12 · 2016: 4
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81322025, 81401735, #81421001, 81371875)
- Foundation for Innovative Research Groups of the National Natural Science Foundation of China (81421001)
- Renji Hospital
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- gefitinib resistance, STAT3 activation, colorectal cancer, EGFR tyrosine kinase inhibitor resistance, Stattic, STAT3 inhibition, tumor suppressor gene reactivation, drug resistance mechanisms
- MeSH terms
- Gefitinib, Thyroid Hormone-Binding Proteins, Antineoplastic Agents, Carrier Proteins, Cell Line, Cell Nucleus, Humans, Membrane Proteins, Quinazolines, Thyroid Hormones, Colorectal Neoplasms, Transcriptional Activation, Up-Regulation, Drug Resistance, Neoplasm, HT29 Cells, HCT116 Cells, Cell Line, Tumor, Protein Kinase Inhibitors, STAT3 Transcription Factor, HEK293 Cells, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.